Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA

Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB–positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was...

Descripción completa

Detalles Bibliográficos
Autores principales: Trieu, Lisa, Proops, Douglas C., Ahuja, Shama D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2015
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344279/
https://www.ncbi.nlm.nih.gov/pubmed/25695482
http://dx.doi.org/10.3201/eid2103.141313
_version_ 1782359395788652544
author Trieu, Lisa
Proops, Douglas C.
Ahuja, Shama D.
author_facet Trieu, Lisa
Proops, Douglas C.
Ahuja, Shama D.
author_sort Trieu, Lisa
collection PubMed
description Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB–positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was generally well-tolerated; further research of its efficacy against MDR TB is needed.
format Online
Article
Text
id pubmed-4344279
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-43442792015-03-02 Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA Trieu, Lisa Proops, Douglas C. Ahuja, Shama D. Emerg Infect Dis Dispatch Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB–positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was generally well-tolerated; further research of its efficacy against MDR TB is needed. Centers for Disease Control and Prevention 2015-03 /pmc/articles/PMC4344279/ /pubmed/25695482 http://dx.doi.org/10.3201/eid2103.141313 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Trieu, Lisa
Proops, Douglas C.
Ahuja, Shama D.
Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
title Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
title_full Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
title_fullStr Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
title_full_unstemmed Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
title_short Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
title_sort moxifloxacin prophylaxis against mdr tb, new york, new york, usa
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344279/
https://www.ncbi.nlm.nih.gov/pubmed/25695482
http://dx.doi.org/10.3201/eid2103.141313
work_keys_str_mv AT trieulisa moxifloxacinprophylaxisagainstmdrtbnewyorknewyorkusa
AT proopsdouglasc moxifloxacinprophylaxisagainstmdrtbnewyorknewyorkusa
AT ahujashamad moxifloxacinprophylaxisagainstmdrtbnewyorknewyorkusa

Ejemplares similares